Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fusion Antibodies Plc ( (GB:FAB) ) has issued an announcement.
Fusion Antibodies plc has conditionally raised approximately £1.4 million before expenses via a non-pre-emptive placing and subscription of just over 11 million new ordinary shares at 13 pence, matching the previous day’s closing bid price. The capital injection, supported by existing and new investors and including a direct subscription by non-executive director Colin Walsh, will fund the accelerated commercial rollout of its newly validated OptiMAL® platform, associated lab equipment, expanded global marketing and broader working capital needs. The fundraising follows successful validation and formal launch of OptiMAL® in collaboration with the US National Cancer Institute and strong early market interest, which has already generated a sales pipeline with potential contract value exceeding £1 million; management argues that raising funds now will allow the company to seize this growth opportunity rather than constrain investment to maintain cash breakeven, potentially strengthening its competitive position in antibody discovery services and underpinning long-term shareholder value.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc, listed on AIM, specialises in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications. The company focuses on proprietary technology platforms such as OptiMAL®, OptiPhage™ and AI/ML-ab™ to support biopharmaceutical clients in developing new antibody therapeutics, with a growing commercial emphasis on key markets including North America.
Average Trading Volume: 843,964
Technical Sentiment Signal: Buy
Current Market Cap: £15.34M
For an in-depth examination of FAB stock, go to TipRanks’ Overview page.